BioSpace News Archive

Jasper Therapeutics, Inc. announced results for the fiscal quarter ended March 31, 2024, and reported recent corporate developments.

Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced financial results for the first quarter of 2024 and provided a corporate update.

Provectus Biopharmaceuticals, Inc. were presented at the annual meeting of the Association for Research in Vision and Ophthalmology (“ARVO”), held May 5-9, 2024 in Seattle, Washington.

Palisade Bio, Inc. today reported its financial results for the first quarter 2024 and provided a business update.

Ocugen, Inc. today reported first quarter 2024 financial results along with a general business update.

Halia Therapeutics today announced the unveiling of a new clinical program evaluating its candidate HT-4253 for the treatment of Alzheimer’s disease.

Precision for Medicine, a global leader in biomarker-driven clinical research and development supporting life sciences companies, announced the completion of a major expansion to its laboratory campus in Frederick, Maryland.

Verismo Therapeutics today announced that it has received a notification from the US Food and Drug Administration (FDA) that the Phase 1 clinical trial of SynKIR™-310 for the investigation of NHL may proceed.

Scholar Rock today announced it will host an Investor Day on Wednesday, May 22, 2024 beginning at 8:30 a.m. ET in New York City.

Allurion Technologies, Inc. today announced its financial results for the first quarter ended March 31, 2024, and provided a business update.